Pricing key after EU blesses AbbVie hep C breakthroughs
This article was originally published in Scrip
Executive Summary
AbbVie's hepatitis C drugs, Exviera (dasabuvir) and Viekirax (ombitasvir plus paritaprevir plus ritonavir) have got the all clear from the EU's CHMP after an accelerated assessment. However, if AbbVie wants to compete effectively with Gilead's own breakthroughs, it will likely have to work on price.